Mosaic Window

Availability

The use of this dataset is free but requires to users to be habilitated through a research objective that is reviewed by the producing consortium. This dataset can be made available for a trial on K Pro tool at your request.

MOSAIC Window is a curated subset of the groundbreaking MOSAIC dataset, available through K Pro. It includes spatial omics and multimodal data from 100 patients across 8 cancer types:

• BLCA (Bladder Cancer): 15 patients
• OV (Ovarian Cancer): 15 patients
• GBM (Glioblastoma): 10 patients
• DLBCL (Diffuse Large B-cell Lymphoma): 10 patients
• MESO (Mesothelioma): 10 patients
• NSCLC (Non-Small Cell Lung Cancer): 15 patients
• HNSCC (Head & Neck Squamous Cell Carcinomas): 10 patients
• BRCA (Breast Cancer): 15 patients

This unique resource enables researchers to explore tumor biology at near single-cell resolution, providing detailed insight into tumor and immune cell interactions.

MOSAIC Window Patient Details

BLCA (15 patients):

• Stage II and III urothelial carcinoma (one squamous cell carcinoma)
• Derived from upfront cystectomies
• Most patients receiving complete lymph node dissection
• Some treated with adjuvant chemotherapy, chemotherapy, or immune checkpoint inhibitors (ICI) at relapse, with or without radiotherapy

OV (15 patients):

• FIGO stage II to IV high grade serous carcinoma
• 7 baseline, 2 post-NACT, 6 relapse lesions
• Treated by upfront or post-NACT interval debulking surgeries and chemotherapy
• Additional treatments: Bevacizumab, PARP inhibitors, and ICI in first or later lines

GBM (10 patients):

• Glioblastoma as per WHO 2021 definition, all IDH wildtype
• 6 unmethylated and 4 methylated MGMT promoter samples
• Obtained from baseline surgery before standard adjuvant therapy
• 1 to 3 brain tumor sites, tumor sizes 27 to 80mm diameter
• 5 patients received Bevacizumab at relapse

DLBCL (10 patients):

• Ann Arbor stage III or IV
• 3 Activated B-cell-like type (ABC), 6 Germinal center B-cell group (GCB), 1 unknown subtype
• Obtained at baseline before R-CHOP therapy
• Targeted interventions at relapse

MESO (10 patients):

• Stage I to III pleural mesotheliomas
• 5 epithelioid, 5 biphasic
• 9 baseline biopsies/surgeries, 1 post-NACT sample
• 4 patients treated by NACT (1 partial response, 3 progressive diseases)
• 4 patients received anti-PD-1 ICI at relapse (monotherapy or combination with anti-CTLA4)

NSCLC (15 patients):

• 10 Adenocarcinoma and 5 squamous cell carcinoma
• Male-predominant (10/15)
• 8 patients ≥ 70 years old
• Mostly early-to-intermediate stage at diagnosis (Stage I: 5, Stage II: 4, Stage III: 2, Stage IV: 1)
• 50% former smokers, 29% active smokers and 21% never smokers 21.4%
• 14 patients received surgical resection
• 4 patients with KEAP1 mutations, 2 patients with TP53 mutations and 1 patient with a co-mutation of KEAP1+STK11
• 9 patients had upfront surgery, 3 patients had neoadjuvant chemotherapy (NACT) before surgery and 1 patient had initial 1L immunotherapy combination with chemotherapy for a metastatic disease.
• 11 samples are from baseline surgery, 3 from post-NACT surgical samples and 1 baseline sample for the patient treated with upfront chemotherapy + immunotherapy

HNSCC (10 patients):

• 6 male patients , mostly between 50 and 69 years old
• Majority of patients were advanced-stage at diagnosis — Stage IV (5), Stage III (2)
• All the patients received immunotherapy in the Recurrent Unresectable and/or Metastatic (R/M) setting.
• 9/10 patients had surgical resection.
• 4 active smokers, 5 former smokers, 1 never-smoker
• 3 patients had CPS > 20
• 1 patient has positive HPV status by p16 IHC
• 6 patients had upfront surgery with various adjuvant strategies and 2 patients had initial 1L anti-PD1 treatment
• 6 patients have paired samples from primary tumour and recurrence, including 1 patient with an additional post-Immunotherapy progression sample

BRCA (15 patients):

• 10 patients had infiltrating ductal adenocarcinoma
• 10 patients had triple-negative breast cancer (TNBC)
• Mostly early/intermediate stage disease at diagnosis— Stage I (3), II (7), III (2)
• 8 patients were postmenopausal and 7 were premenopausal
• All patients are BRCA1 / BRCA2 wild-type, and 2 patients had PIK3CA mutations
• 9 patients were treated with neoadjuvant chemotherapy (NACT) before surgery
• 2 patients have paired samples at baseline and post-NACT surgery, including 1 patient with an additional sample at disease recurrence.
• 4 other patients have paired samples at post-NACT surgery and disease recurrence.
• 1 samples is from a baseline metastatic site